{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T12:27:38Z","timestamp":1794400058786,"version":"4.9.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T00:00:00Z","timestamp":1665187200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T00:00:00Z","timestamp":1665187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In early systemic sclerosis (Scleroderma, SSc), the vasculature is impaired. Although the exact etiology of endothelial cell damage in SSc remains unclear, it is hypothesized that endothelial to mesenchymal transition (EndoMT) plays a key role. To perform physiologically relevant angiogenic studies, we set out to develop an angiogenesis-on-a-chip platform that is suitable for assessing disease parameters that are relevant to SSc and other vasculopathies. In the model, we substituted Fetal Bovine Serum (FBS) with Human Serum without impairing the stability of the culture. We showed that 3D microvessels and angiogenic factor-induced sprouts exposed to key pro-inflammatory and pro-fibrotic cytokines (TNF\u03b1 and TGF\u03b2) undergo structural alterations consisting of destructive vasculopathy (loss of small vessels). We also showed that these detrimental effects can be prevented by compound-mediated inhibition of TGF\u03b2-ALK5 signaling or addition of a TNF\u03b1 neutralizing antibody to the 3D cultures. This demonstrates that our in vitro model is suitable for compound testing and identification of new drugs that can protect from microvascular destabilization or regression in disease-mimicking conditions. To support this, we demonstrated that sera obtained from SSc patients can exert an anti-angiogenic effect on the 3D vessel model, opening the doors to screening for potential SSc drugs, enabling direct patient translatability and personalization of drug treatment.<\/jats:p>","DOI":"10.1038\/s41598-022-21468-x","type":"journal-article","created":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T10:04:53Z","timestamp":1665223493000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["High-throughput 3D microvessel-on-a-chip model to study defective angiogenesis in systemic sclerosis"],"prefix":"10.1038","volume":"12","author":[{"given":"Bart","family":"Kramer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Corallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelique","family":"van den Heuvel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Olivier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edo","family":"Elstak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Vulto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henriette L.","family":"Lanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A. J.","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela A.","family":"Tessari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,8]]},"reference":[{"key":"21468_CR1","doi-asserted-by":"crossref","unstructured":"Denton, C. P. Advances in pathogenesis and treatment of systemic sclerosis. Clin. Med. J. R. Coll. Physicians London 15, s58\u2013s63 (2015).","DOI":"10.7861\/clinmedicine.15-6-s58"},{"key":"21468_CR2","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.rdc.2007.12.004","volume":"34","author":"B Kahaleh","year":"2008","unstructured":"Kahaleh, B. Vascular disease in scleroderma: Mechanisms of vascular injury. Rheum. Dis. Clin. North Am. 34, 57\u201371 (2008).","journal-title":"Rheum. Dis. Clin. North Am."},{"key":"21468_CR3","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1002\/jcp.10333","volume":"196","author":"C Michiels","year":"2003","unstructured":"Michiels, C. Endothelial cell functions. J. Cell. Physiol. 196, 430\u2013443 (2003).","journal-title":"J. Cell. Physiol."},{"key":"21468_CR4","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1002\/art.37988","volume":"65","author":"M Matucci-Cerinic","year":"2013","unstructured":"Matucci-Cerinic, M., Kahaleh, B. & Wigley, F. M. Review: Evidence that systemic sclerosis is a vascular disease. Arthritis Rheum. 65, 1953\u20131962 (2013).","journal-title":"Arthritis Rheum."},{"key":"21468_CR5","doi-asserted-by":"crossref","unstructured":"Cantatore, F. P., Maruotti, N., Corrado, A. & Ribatti, D. Angiogenesis dysregulation in the pathogenesis of systemic sclerosis. Biomed Res. Int. 2017, (2017).","DOI":"10.1155\/2017\/5345673"},{"key":"21468_CR6","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/annrheumdis-2016-210229","volume":"76","author":"M Manetti","year":"2017","unstructured":"Manetti, M. et al. Endothelial-to-mesenchymal transition contributes to endothelial dysfunction and dermal fibrosis in systemic sclerosis. Ann. Rheum. Dis. 76, 924\u2013934 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"21468_CR7","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1177\/0961203309346654","volume":"18","author":"DS Domiciano","year":"2009","unstructured":"Domiciano, D. S., Carvalho, J. F. & Shoenfeld, Y. Pathogenic role of anti-endothelial cell antibodies in autoimmune rheumatic diseases. Lupus 18, 1233\u20131238 (2009).","journal-title":"Lupus"},{"key":"21468_CR8","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.it.2005.03.006","volume":"26","author":"P Meroni","year":"2005","unstructured":"Meroni, P., Ronda, N., Raschi, E. & Borghi, M. O. Humoral autoimmunity against endothelium: Theory or reality?. Trends Immunol. 26, 275\u2013281 (2005).","journal-title":"Trends Immunol."},{"key":"21468_CR9","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1177\/0394632015572750","volume":"28","author":"C Corallo","year":"2015","unstructured":"Corallo, C. et al. From microvasculature to fibroblasts: Contribution of anti-endothelial cell antibodies in systemic sclerosis. Int. J. Immunopathol. Pharmacol. 28, 93\u2013103 (2015).","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"21468_CR10","doi-asserted-by":"crossref","unstructured":"Katsumoto, T. R., Violette, S. M. & Sheppard, D. Blocking TGF\u03b2 via inhibition of the \u03b1v\u03b26 integrin: A possible therapy for systemic sclerosis interstitial lung disease. Int. J. Rheumatol. 2011, (2011).","DOI":"10.1155\/2011\/208219"},{"key":"21468_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2018.01985","volume":"9","author":"DTB Thuan","year":"2018","unstructured":"Thuan, D. T. B. et al. A potential link between oxidative stress and endothelial-to-mesenchymal transition in systemic sclerosis. Front. Immunol. 9, 1\u201314 (2018).","journal-title":"Front. Immunol."},{"key":"21468_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-020-02360-3","volume":"22","author":"E Raschi","year":"2020","unstructured":"Raschi, E. et al. Scleroderma-specific autoantibodies embedded in immune complexes mediate endothelial damage: An early event in the pathogenesis of systemic sclerosis. Arthritis Res. Ther. 22, 1\u201317 (2020).","journal-title":"Arthritis Res. Ther."},{"key":"21468_CR13","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.autrev.2006.12.006","volume":"6","author":"S Guiducci","year":"2007","unstructured":"Guiducci, S., Giacomelli, R. & Cerinic, M. M. Vascular complications of scleroderma. Autoimmun. Rev. 6, 520\u2013523 (2007).","journal-title":"Autoimmun. Rev."},{"key":"21468_CR14","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1136\/ard.2007.072686","volume":"67","author":"SI Nihtyanova","year":"2008","unstructured":"Nihtyanova, S. I., Brough, G. M., Black, C. M. & Denton, C. P. Clinical burden of digital vasculopathy in limited and diffuse cutaneous systemic sclerosis. Ann. Rheum. Dis. 67, 120\u2013123 (2008).","journal-title":"Ann. Rheum. Dis."},{"key":"21468_CR15","first-page":"182","volume":"33","author":"N Giordano","year":"2015","unstructured":"Giordano, N. et al. Pulmonary hypertension: A correct diagnosis for a suitable therapy in scleroderma patients. Clin. Exp. Rheumatol. 33, 182\u2013189 (2015).","journal-title":"Clin. Exp. Rheumatol."},{"key":"21468_CR16","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00281-015-0505-5","volume":"37","author":"Y Asano","year":"2015","unstructured":"Asano, Y. & Sato, S. Vasculopathy in scleroderma. Semin. Immunopathol. 37, 489\u2013500 (2015).","journal-title":"Semin. Immunopathol."},{"key":"21468_CR17","first-page":"65","volume":"6","author":"CM Artlett","year":"2014","unstructured":"Artlett, C. M. Animal models of systemic sclerosis: Their utility and limitations. Open Access Rheumatol. Res. Rev. 6, 65\u201381 (2014).","journal-title":"Open Access Rheumatol. Res. Rev."},{"key":"21468_CR18","doi-asserted-by":"crossref","unstructured":"Staton, C. A. et al. Current methods for assaying angiogenesis in vitro and in vivo international experimental. 233\u2013248 (2004).","DOI":"10.1111\/j.0959-9673.2004.00396.x"},{"key":"21468_CR19","doi-asserted-by":"crossref","unstructured":"Mazzotta, C. et al. Proangiogenic effects of soluble \u03b1-Klotho on systemic sclerosis dermal microvascular endothelial cells. Arthritis Res. Ther. 19, (2017).","DOI":"10.1186\/s13075-017-1233-0"},{"key":"21468_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0130166","volume":"10","author":"A Borghini","year":"2015","unstructured":"Borghini, A. et al. Systemic sclerosis sera impair angiogenic performance of dermal microvascular endothelial cells: Therapeutic implications of cyclophosphamide. PLoS ONE 10, 1\u201318 (2015).","journal-title":"PLoS ONE"},{"key":"21468_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-016-1122-y","volume":"18","author":"C Corallo","year":"2016","unstructured":"Corallo, C. et al. Bosentan and macitentan prevent the endothelial-to-mesenchymal transition (EndoMT) in systemic sclerosis: In vitro study. Arthritis Res. Ther. 18, 1\u20139 (2016).","journal-title":"Arthritis Res. Ther."},{"key":"21468_CR22","first-page":"148","volume":"33","author":"E Romano","year":"2015","unstructured":"Romano, E. et al. Bosentan blocks the antiangiogenic effects of sera from systemic sclerosis patients: An in vitro study. Clin. Exp. Rheumatol. 33, 148\u2013152 (2015).","journal-title":"Clin. Exp. Rheumatol."},{"key":"21468_CR23","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nprot.2007.30","volume":"2","author":"CC Liang","year":"2007","unstructured":"Liang, C. C., Park, A. Y. & Guan, J. L. In vitro scratch assay: A convenient and inexpensive method for analysis of cell migration in vitro. Nat. Protoc. 2, 329\u2013333 (2007).","journal-title":"Nat. Protoc."},{"key":"21468_CR24","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/j.1365-2613.2008.00633.x","volume":"90","author":"CA Staton","year":"2009","unstructured":"Staton, C. A., Reed, M. W. R. & Brown, N. J. A critical analysis of current in vitro and in vivo angiogenesis assays. Int. J. Exp. Pathol. 90, 195\u2013221 (2009).","journal-title":"Int. J. Exp. Pathol."},{"key":"21468_CR25","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1177\/1535370214539228","volume":"239","author":"A Tourovskaia","year":"2014","unstructured":"Tourovskaia, A., Fauver, M., Kramer, G., Simonson, S. & Neumann, T. Tissue-engineered microenvironment systems for modeling human vasculature. Exp. Biol. Med. (Maywood) 239, 1264\u20131271 (2014).","journal-title":"Exp. Biol. Med. (Maywood)"},{"key":"21468_CR26","doi-asserted-by":"publisher","first-page":"6712","DOI":"10.1073\/pnas.1221526110","volume":"110","author":"D-HT Nguyen","year":"2013","unstructured":"Nguyen, D.-H.T. et al. Biomimetic model to reconstitute angiogenic sprouting morphogenesis in vitro. Proc. Natl. Acad. Sci. U. S. A. 110, 6712\u20136717 (2013).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"21468_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.cobme.2017.02.002","author":"A Junaid","year":"2017","unstructured":"Junaid, A., Mashaghi, A., Hankemeier, T. & Vulto, P. An end-user perspective on organ-on-a-chip: assays and usability aspects. Curr. Opin. Biomed. Eng. https:\/\/doi.org\/10.1016\/j.cobme.2017.02.002 (2017).","journal-title":"Curr. Opin. Biomed. Eng."},{"key":"21468_CR28","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s10456-018-9647-0","volume":"22","author":"V van Duinen","year":"2019","unstructured":"van Duinen, V. et al. Perfused 3D angiogenic sprouting in a high-throughput in vitro platform. Angiogenesis 22, 157\u2013165 (2019).","journal-title":"Angiogenesis"},{"key":"21468_CR29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms21134804","volume":"21","author":"V van Duinen","year":"2020","unstructured":"van Duinen, V. et al. Robust and scalable angiogenesis assay of perfused 3D human ipsc-derived endothelium for anti-angiogenic drug screening. Int. J. Mol. Sci. 21, 1\u20139 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"21468_CR30","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1002\/art.38098","volume":"65","author":"F Van Den Hoogen","year":"2013","unstructured":"Van Den Hoogen, F. et al. 2013 classification criteria for systemic sclerosis: An american college of rheumatology\/European league against rheumatism collaborative initiative. Arthritis Rheum. 65, 2737\u20132747 (2013).","journal-title":"Arthritis Rheum."},{"key":"21468_CR31","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin, J. et al. Fiji: An open-source platform for biological-image analysis. Nat. Methods 9, 676\u2013682 (2012).","journal-title":"Nat. Methods"},{"key":"21468_CR32","doi-asserted-by":"crossref","unstructured":"Sternberg, S. Biomedical Image Processing. Computer (Long. Beach. Calif). 22\u201335 (1983).","DOI":"10.1109\/MC.1983.1654163"},{"key":"21468_CR33","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/S0167-8655(98)00057-9","volume":"19","author":"CH Li","year":"1998","unstructured":"Li, C. H. & Tam, P. K. S. An iterative algorithm for minimum cross entropy thresholding. Pattern Recognit. Lett. 19, 771\u2013776 (1998).","journal-title":"Pattern Recognit. Lett."},{"key":"21468_CR34","doi-asserted-by":"publisher","first-page":"616","DOI":"10.2353\/ajpath.2009.081061","volume":"175","author":"A Kitao","year":"2009","unstructured":"Kitao, A. et al. Endothelial to mesenchymal transition via transforming growth factor-\u03b21\/smad activation is associated with portal venous stenosis in idiopathic portal hypertension. Am. J. Pathol. 175, 616\u2013626 (2009).","journal-title":"Am. J. Pathol."},{"key":"21468_CR35","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.3899\/jrheum.150088","volume":"42","author":"P Cipriani","year":"2015","unstructured":"Cipriani, P. et al. The endothelial-mesenchymal transition in systemic sclerosis is induced by endothelin-1 and transforming growth factor-\u03b2 and may be blocked by Macitentan, a dual endothelin-1 receptor antagonist. J. Rheumatol. 42, 1808\u20131816 (2015).","journal-title":"J. Rheumatol."},{"issue":"6","key":"21468_CR36","first-page":"283","volume":"2014","author":"G Murdaca","year":"2014","unstructured":"Murdaca, G. & Contatore, M. Murdaca 2014(6), 283\u2013289 (2014).","journal-title":"Murdaca"},{"key":"21468_CR37","doi-asserted-by":"crossref","unstructured":"Manetti, M. et al. Systemic sclerosis serum significantly impairs the multi-step lymphangiogenic process: In vitro evidence. Int. J. Mol. Sci. 20, (2019).","DOI":"10.3390\/ijms20246189"},{"key":"21468_CR38","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.phrs.2018.11.002","volume":"139","author":"M Weinhart","year":"2019","unstructured":"Weinhart, M., Hocke, A., Hippenstiel, S., Kurreck, J. & Hedtrich, S. 3D organ models\u2014Revolution in pharmacological research?. Pharmacol. Res. 139, 446\u2013451 (2019).","journal-title":"Pharmacol. Res."},{"key":"21468_CR39","doi-asserted-by":"crossref","unstructured":"Hoarau-V\u00e9chot, J., Rafii, A., Touboul, C. & Pasquier, J. Halfway between 2D and animal models: Are 3D cultures the ideal tool to study cancer-microenvironment interactions? Int. J. Mol. Sci. 19, (2018).","DOI":"10.3390\/ijms19010181"},{"key":"21468_CR40","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1038\/424870a","volume":"424","author":"A Abbott","year":"2003","unstructured":"Abbott, A. Biology\u2019s new dimension. Nature 424, 870\u2013872 (2003).","journal-title":"Nature"},{"key":"21468_CR41","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.cobme.2017.02.002","volume":"1","author":"A Junaid","year":"2017","unstructured":"Junaid, A., Mashaghi, A., Hankemeier, T. & Vulto, P. An end-user perspective on Organ-on-a-Chip: Assays and usability aspects. Curr. Opin. Biomed. Eng. 1, 15\u201322 (2017).","journal-title":"Curr. Opin. Biomed. Eng."},{"key":"21468_CR42","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12987-018-0108-3","volume":"15","author":"NR Wevers","year":"2018","unstructured":"Wevers, N. R. et al. A perfused human blood\u2013brain barrier on-a-chip for high-throughput assessment of barrier function and antibody transport. Fluids Barriers CNS 15, 23 (2018).","journal-title":"Fluids Barriers CNS"},{"key":"21468_CR43","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1038\/s41596-020-00479-w","volume":"16","author":"L Gijzen","year":"2021","unstructured":"Gijzen, L. et al. Culture and analysis of kidney tubuloids and perfused tubuloid cells-on-a-chip. Nat. Protoc. 16, 2023\u20132050 (2021).","journal-title":"Nat. Protoc."},{"key":"21468_CR44","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1186\/s12885-017-3709-3","volume":"17","author":"HL Lanz","year":"2017","unstructured":"Lanz, H. L. et al. Therapy response testing of breast cancer in a 3D high-throughput perfused microfluidic platform. BMC Cancer 17, 709 (2017).","journal-title":"BMC Cancer"},{"key":"21468_CR45","doi-asserted-by":"crossref","unstructured":"Kramer, B. et al. Interstitial flow recapitulates gemcitabine chemoresistance in a 3D microfluidic pancreatic ductal adenocarcinoma model by induction of multidrug resistance proteins. Int. J. Mol. Sci. 20, (2019).","DOI":"10.3390\/ijms20184647"},{"key":"21468_CR46","first-page":"47","volume":"37","author":"C Poussin","year":"2020","unstructured":"Poussin, C. et al. 3D human microvessel-on-a-chip model for studying monocyte-to-endothelium adhesion under flow - Application in systems toxicology. Altex 37, 47\u201363 (2020).","journal-title":"Altex"},{"key":"21468_CR47","unstructured":"Zonneveld et al. Standardized and scalable assay to study perfused 3d angiogenic sprouting of ipsc-derived endothelial cells in vitro. J. Vis. Exp. 2019, (2019)."},{"key":"21468_CR48","doi-asserted-by":"crossref","unstructured":"Vulto, P. & Joore, J. Adoption of organ-on-chip platforms by the pharmaceutical industry. Nat. Rev. Drug Discov. (2021).","DOI":"10.1038\/s41573-021-00323-0"},{"key":"21468_CR49","doi-asserted-by":"publisher","first-page":"712","DOI":"10.3109\/14653249.2010.548380","volume":"13","author":"L Huang","year":"2011","unstructured":"Huang, L., Critser, P. J., Grimes, B. R. & Yoder, M. C. Human umbilical cord blood plasma can replace fetal bovine serum for in vitro expansion of functional human endothelial colony-forming cells. Cytotherapy 13, 712\u2013721 (2011).","journal-title":"Cytotherapy"},{"key":"21468_CR50","first-page":"5123","volume":"19","author":"W Tancharoen","year":"2019","unstructured":"Tancharoen, W. et al. Human platelet lysate as an alternative to fetal bovine serum for culture and endothelial differentiation of human amniotic fluid mesenchymal stem cells. Mol. Med. Rep. 19, 5123\u20135132 (2019).","journal-title":"Mol. Med. Rep."},{"key":"21468_CR51","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1136\/bjophthalmol-2014-306034","volume":"99","author":"LMM Vianna","year":"2015","unstructured":"Vianna, L. M. M. et al. Use of human serum for human corneal endothelial cell culture. Br. J. Ophthalmol. 99, 267\u2013271 (2015).","journal-title":"Br. J. Ophthalmol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-21468-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-21468-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-21468-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T21:02:39Z","timestamp":1665262959000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-21468-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,8]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["21468"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-21468-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,8]]},"assertion":[{"value":"8 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Authors BK, AvdH, TO, PV and HLL are or were employees of MIMETAS and PV is shareholder of that same company. The OrganoPlate\u00ae is a registered trademark of MIMETAS BV. Authors CC, JC, EE, RAJJ and MAT are employees of Galapagos (Leiden, The Netherlands and Milan, Italy). The authors declare no competing interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16930"}}